氪黄激光治疗黄斑外息肉状脉络膜血管病变的效果

Abstract
Figure/Table
References (20)
Related Citation (0)

Download: PDF (396 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of krypton yellow laser for polypoidal choroidal vasculopathy (PCV) outside the macular. Methods Eleven cases (11 eyes) with PCV located out of the macular central fovea with 500 μm were selected in Handan City Eye Hospital from June 2015 to June 2017, that were diagnosed by clinical features, medical history, fundus fluorescence angiography (FFA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT). All patients were treated with krypton yellow laser 2-3 times with interval of 15 days to 1 month. The re-treatment indications were according to the color fundus lesions, the reaction of laser, fundus angiography (FFA and ICGA) and OCT examination. All the patients were followed up for 6 to 12 months. Visual acuity, the best corrected visual acuity, FFA, ICGA and OCT results were observed. Results There were 3 eyes that were treated with laser 2 times, while 8 eyes were treated with 3 times. There were 6 patients (6 eyes) replied that the visual acuity improved compared with that before treatment and visual deformation mainly eliminated. There were 2 patients (2 eyes) that had a slightly improvement in the visual acuity and the shadow decreased. Three patients (3 eyes) had significant visual improvement with shadow disappearing. The best corrected vision acuity was 0.1-0.6. FFA and ICG results showed atrophy of PCV lesions. Conclusion Effect of krypton yellow laser treatment for PCV located out of the macular central fovea with 500 μm was reliable, that can stabilize and improve patients′ vision acuity effectively, preventing the further progress of PCV, inexpensive and effective.

Key words： Polypoidal choroidal vasculopathy Krypton yellow laser Fundus fluorescein angiography Optic coherence tomography

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHEN Ran1 WANG Fenghua2▲ GUO Lixia1 YANG Liping1 WANG Yanna1

Cite this article:

SHEN Ran1 WANG Fenghua2▲ GUO Lixia1 YANG Liping1 WANG Yanna1. Efficacy of krypton yellow laser for polypoidal choroidal vasculopathy outside the macular[J]. 中国医药导报, 2018, 15(30): 98-101.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I30/98

[1] Yannuzzi LA，Nogueira FB，Spaide RF，et al. Idiopathic poly-poidal choroidal vasculopathy [J]. Arch Ophthalmol，1998， 116（3）：382-383.
[2] Maruko I，Tida T，Saito M，et al. Clinical characteristics of exudative age-related macular degeneration in Japanecse patients. [J] Am J Ophthalmol，2007，144（1）：15-22.
[3] Liu Y，Wen F，Huiang S，et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients [J] Graefes Arch Clin Exp Ophthalmol，2007，245（10）：1441-1445.
[4] Imamura Y，Engelbert M，Iida T，et al. Polypoidal choroidal vasculopathy：a review [J]. Surv Ophthalmol，2010，55（6）：501-515.
[5] 刘雪霞.息肉样脉络膜血管病变的诊断与治疗进展[J].中华医学眼科杂志：电子版，2013，3（3）：173-176.
[6] Li XX. Polypoidal choroidal vasculopathy [M]. 5th Edition. Amsterdam：Imprint of Elsevier Inc，2013：1285-1290.
[7] 兰贤海，荣翱.息肉状脉络膜血管病变的现代治疗[J].外科研究与新技术，2015，4（3）：204-207.
[8] 苏鹏，晏世刚，孔祥斌，等.光学相干断层扫描在老年性黄斑变性诊断中的应用价值研究[J].中国医药科学，2016，6（4）：192-194，202.
[9] 方廷兵，严浩，吴雪丹.SD-OCT与FFA在白内障术后黄斑囊样水肿中的应用价值[J].中国当代医药，2016，23（32）：108-111.
[10] Coppens G，Spielberg L，Leys A. Polypoidal choroidal vasculopathy，diagnosis and management [J]. Bull Soc Belge Ophtalmol，2011，317：39-44.
[11] 刘姝林，陈有信.息肉状脉络膜血管病变的诊断及治疗进展[J].中华眼视光学与视觉科学杂志，2012，14（8）：509-512.
[12] Gomi F，Sawa M，Wakabayashi T，et al. Eficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy [J]. Am J Ophthalmol，2010，150（1）：48-54.
[13] Hikiehi T，Ohtsuka H，Higuchi M，et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months [J]. Am J Ophthalmol，2010，51（13）：516.
[14] Gomi F，Sawa M，Sakaguchi H，et al. Eficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy [J]. Br J Ophthalmol，2008，92（1）：70-73.
[15] Sato T，Kishi S，Matsumoto H，et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy [J]. Am J Ophthalmol，2010，149（6）：947-954.
[16] Lai TY，Lee GK，Luk FO，et al. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy [J]. Retina，2011，31（8）：1581-1588.
[17] Hikichi T，Higuchi M，Matsushita T，et al. One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients [J]. Am J Ophthalmol，2012，154（1）：117-124.
[18] Tomita K，Tsujikawa A，Yamashiro K，et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab [J]. Am J Ophthalmol，2012，153（1）：68-80.
[19] Nishijima K，Takahashi M，Akita J，et al. Laser photocoagulation. of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy [J]. Am J Ophthalmol，2004，137（4）：770-773.
[20] Yuzawa M，Mori R，Haruyama M. A study of laser photocoagulation for polypoidal choroidal vasculopathy [J]. Jpn J Ophthalmol，2003，47（4）：379-384.